MRP- and BCL-2-mediated drug resistance in human SCLC: Effects of apoptotic sphingolipids in vitro

M. Khodadadian, M. E. Leroux, E. Auzenne, S. C. Ghosh, D. Farquhar, R. Evans, W. Spohn, Yiyu Zou, J. Klostergaard

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Multidrug-resistance-associated protein (MRP) and BCL-2 contribute to drug resistance expressed in SCLC. To establish whether MRP-mediated drug resistance affects sphingolipid (SL)-induced apoptosis in SCLC, we first examined the human SCLC cell line, UMCC-1, and its MRP over-expressing, drug-resistant subline, UMCC-1/VP. Despite significantly decreased sensitivity to doxorubicin (Dox) and to the etoposide, VP-16, the drug-selected line was essentially equally as sensitive to treatment with exogenous ceramide (Cer), sphingosine (Sp) or dimethyl-sphingosine (DMSP) as the parental line. Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were ∼160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only ∼5-fold more resistant to DMSP. Time-lapse fluorescence microscopy of either UMCC cell line treated with DMSP-Coumarin revealed comparable extents and kinetics of SL uptake, further ruling out MRP-mediated effects on drug uptake. DMSP potentiated the cytotoxic activity of VP-16 and Taxol, but not Dox, in drug-resistant UMCC-1/VP cells. However, this sensitization did not appear to involve DMSP-mediated effects on the function of MRP in drug export; nor did DMSP strongly shift the balance of pro-apoptotic Sps and anti-apoptotic Sp-1-Ps in these cells. We conclude that SL-induced apoptosis markedly overcomes or bypasses MRP-mediated drug resistance relevant to SCLC and may suggest a novel therapeutic approach to chemotherapy for these tumors.

Original languageEnglish (US)
Pages (from-to)48-57
Number of pages10
JournalLung Cancer
Volume66
Issue number1
DOIs
StatePublished - Oct 2009

Fingerprint

Sphingolipids
Sphingosine
Drug Resistance
Multidrug Resistance-Associated Proteins
Etoposide
Doxorubicin
Viral Structural Proteins
Pharmaceutical Preparations
Apoptosis
Cell Line
multidrug resistance-associated protein 2
In Vitro Techniques
Ceramides
Paclitaxel
Fluorescence Microscopy
Drug Therapy
Therapeutics

Keywords

  • Apoptosis
  • Doxorubicin
  • Drug resistance
  • MRP
  • SCLC
  • Sphingolipids
  • Taxol
  • VP-16

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Khodadadian, M., Leroux, M. E., Auzenne, E., Ghosh, S. C., Farquhar, D., Evans, R., ... Klostergaard, J. (2009). MRP- and BCL-2-mediated drug resistance in human SCLC: Effects of apoptotic sphingolipids in vitro. Lung Cancer, 66(1), 48-57. https://doi.org/10.1016/j.lungcan.2009.01.006

MRP- and BCL-2-mediated drug resistance in human SCLC : Effects of apoptotic sphingolipids in vitro. / Khodadadian, M.; Leroux, M. E.; Auzenne, E.; Ghosh, S. C.; Farquhar, D.; Evans, R.; Spohn, W.; Zou, Yiyu; Klostergaard, J.

In: Lung Cancer, Vol. 66, No. 1, 10.2009, p. 48-57.

Research output: Contribution to journalArticle

Khodadadian, M, Leroux, ME, Auzenne, E, Ghosh, SC, Farquhar, D, Evans, R, Spohn, W, Zou, Y & Klostergaard, J 2009, 'MRP- and BCL-2-mediated drug resistance in human SCLC: Effects of apoptotic sphingolipids in vitro', Lung Cancer, vol. 66, no. 1, pp. 48-57. https://doi.org/10.1016/j.lungcan.2009.01.006
Khodadadian, M. ; Leroux, M. E. ; Auzenne, E. ; Ghosh, S. C. ; Farquhar, D. ; Evans, R. ; Spohn, W. ; Zou, Yiyu ; Klostergaard, J. / MRP- and BCL-2-mediated drug resistance in human SCLC : Effects of apoptotic sphingolipids in vitro. In: Lung Cancer. 2009 ; Vol. 66, No. 1. pp. 48-57.
@article{55ee8efc35bf4a20babbe5de54b2274b,
title = "MRP- and BCL-2-mediated drug resistance in human SCLC: Effects of apoptotic sphingolipids in vitro",
abstract = "Multidrug-resistance-associated protein (MRP) and BCL-2 contribute to drug resistance expressed in SCLC. To establish whether MRP-mediated drug resistance affects sphingolipid (SL)-induced apoptosis in SCLC, we first examined the human SCLC cell line, UMCC-1, and its MRP over-expressing, drug-resistant subline, UMCC-1/VP. Despite significantly decreased sensitivity to doxorubicin (Dox) and to the etoposide, VP-16, the drug-selected line was essentially equally as sensitive to treatment with exogenous ceramide (Cer), sphingosine (Sp) or dimethyl-sphingosine (DMSP) as the parental line. Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were ∼160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only ∼5-fold more resistant to DMSP. Time-lapse fluorescence microscopy of either UMCC cell line treated with DMSP-Coumarin revealed comparable extents and kinetics of SL uptake, further ruling out MRP-mediated effects on drug uptake. DMSP potentiated the cytotoxic activity of VP-16 and Taxol, but not Dox, in drug-resistant UMCC-1/VP cells. However, this sensitization did not appear to involve DMSP-mediated effects on the function of MRP in drug export; nor did DMSP strongly shift the balance of pro-apoptotic Sps and anti-apoptotic Sp-1-Ps in these cells. We conclude that SL-induced apoptosis markedly overcomes or bypasses MRP-mediated drug resistance relevant to SCLC and may suggest a novel therapeutic approach to chemotherapy for these tumors.",
keywords = "Apoptosis, Doxorubicin, Drug resistance, MRP, SCLC, Sphingolipids, Taxol, VP-16",
author = "M. Khodadadian and Leroux, {M. E.} and E. Auzenne and Ghosh, {S. C.} and D. Farquhar and R. Evans and W. Spohn and Yiyu Zou and J. Klostergaard",
year = "2009",
month = "10",
doi = "10.1016/j.lungcan.2009.01.006",
language = "English (US)",
volume = "66",
pages = "48--57",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - MRP- and BCL-2-mediated drug resistance in human SCLC

T2 - Effects of apoptotic sphingolipids in vitro

AU - Khodadadian, M.

AU - Leroux, M. E.

AU - Auzenne, E.

AU - Ghosh, S. C.

AU - Farquhar, D.

AU - Evans, R.

AU - Spohn, W.

AU - Zou, Yiyu

AU - Klostergaard, J.

PY - 2009/10

Y1 - 2009/10

N2 - Multidrug-resistance-associated protein (MRP) and BCL-2 contribute to drug resistance expressed in SCLC. To establish whether MRP-mediated drug resistance affects sphingolipid (SL)-induced apoptosis in SCLC, we first examined the human SCLC cell line, UMCC-1, and its MRP over-expressing, drug-resistant subline, UMCC-1/VP. Despite significantly decreased sensitivity to doxorubicin (Dox) and to the etoposide, VP-16, the drug-selected line was essentially equally as sensitive to treatment with exogenous ceramide (Cer), sphingosine (Sp) or dimethyl-sphingosine (DMSP) as the parental line. Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were ∼160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only ∼5-fold more resistant to DMSP. Time-lapse fluorescence microscopy of either UMCC cell line treated with DMSP-Coumarin revealed comparable extents and kinetics of SL uptake, further ruling out MRP-mediated effects on drug uptake. DMSP potentiated the cytotoxic activity of VP-16 and Taxol, but not Dox, in drug-resistant UMCC-1/VP cells. However, this sensitization did not appear to involve DMSP-mediated effects on the function of MRP in drug export; nor did DMSP strongly shift the balance of pro-apoptotic Sps and anti-apoptotic Sp-1-Ps in these cells. We conclude that SL-induced apoptosis markedly overcomes or bypasses MRP-mediated drug resistance relevant to SCLC and may suggest a novel therapeutic approach to chemotherapy for these tumors.

AB - Multidrug-resistance-associated protein (MRP) and BCL-2 contribute to drug resistance expressed in SCLC. To establish whether MRP-mediated drug resistance affects sphingolipid (SL)-induced apoptosis in SCLC, we first examined the human SCLC cell line, UMCC-1, and its MRP over-expressing, drug-resistant subline, UMCC-1/VP. Despite significantly decreased sensitivity to doxorubicin (Dox) and to the etoposide, VP-16, the drug-selected line was essentially equally as sensitive to treatment with exogenous ceramide (Cer), sphingosine (Sp) or dimethyl-sphingosine (DMSP) as the parental line. Next, we observed that high BCL-2-expressing human H69 SCLC cells, that were ∼160-fold more sensitive to Dox than their combined BCL-2 and MRP-over-expressing (H69AR) counterparts, were only ∼5-fold more resistant to DMSP. Time-lapse fluorescence microscopy of either UMCC cell line treated with DMSP-Coumarin revealed comparable extents and kinetics of SL uptake, further ruling out MRP-mediated effects on drug uptake. DMSP potentiated the cytotoxic activity of VP-16 and Taxol, but not Dox, in drug-resistant UMCC-1/VP cells. However, this sensitization did not appear to involve DMSP-mediated effects on the function of MRP in drug export; nor did DMSP strongly shift the balance of pro-apoptotic Sps and anti-apoptotic Sp-1-Ps in these cells. We conclude that SL-induced apoptosis markedly overcomes or bypasses MRP-mediated drug resistance relevant to SCLC and may suggest a novel therapeutic approach to chemotherapy for these tumors.

KW - Apoptosis

KW - Doxorubicin

KW - Drug resistance

KW - MRP

KW - SCLC

KW - Sphingolipids

KW - Taxol

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=68949213189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949213189&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.01.006

DO - 10.1016/j.lungcan.2009.01.006

M3 - Article

C2 - 19195736

AN - SCOPUS:68949213189

VL - 66

SP - 48

EP - 57

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -